# Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

> **NCT01333878** · PHASE2,PHASE3 · COMPLETED · sponsor: **Orrin M Troum, M.D. and Medical Associates** · enrollment: 12 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Subcutaneous Abatacept

## Key facts

- **NCT ID:** NCT01333878
- **Lead sponsor:** Orrin M Troum, M.D. and Medical Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-11
- **Final completion:** 2014-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333878, "Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01333878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*